Based on the established benefits of GLP1-RA and SGLT2-i in chronic kidney disease and the promising data about their efficacy and safety after kidney transplantation, the prescription of these novel anti-diabetic agents is expected to grow among kidney transplant recipients. This evidence concerns the gene GLP1R and chronic kidney disease.